These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25652255)

  • 21. Arsenic‑induced BRCA1 CpG promoter methylation is associated with the downregulation of ERα and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
    Selmin OI; Donovan MG; Skovan B; Paine-Murieta GD; Romagnolo DF
    Int J Oncol; 2019 Mar; 54(3):869-878. PubMed ID: 30664189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen Enhances the Cell Viability and Motility of Breast Cancer Cells through the ERα-ΔNp63-Integrin β4 Signaling Pathway.
    Ho JY; Chang FW; Huang FS; Liu JM; Liu YP; Chen SP; Liu YL; Cheng KC; Yu CP; Hsu RJ
    PLoS One; 2016; 11(2):e0148301. PubMed ID: 26845172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
    Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D
    Lundqvist J; Kirkegaard T; Laenkholm AV; Duun-Henriksen AK; Bak M; Feldman D; Lykkesfeldt AE
    J Steroid Biochem Mol Biol; 2018 Mar; 177():171-178. PubMed ID: 28610873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. USP36 promotes tumorigenesis and tamoxifen resistance in breast cancer by deubiquitinating and stabilizing ERα.
    Zhuang T; Zhang S; Liu D; Li Z; Li X; Li J; Yang P; Zhang C; Cui J; Fu M; Shen F; Yuan L; Zhang Z; Su P; Zhu J; Yang H
    J Exp Clin Cancer Res; 2024 Aug; 43(1):249. PubMed ID: 39215346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.
    Hao L; Rizzo P; Osipo C; Pannuti A; Wyatt D; Cheung LW; Sonenshein G; Osborne BA; Miele L
    Oncogene; 2010 Jan; 29(2):201-13. PubMed ID: 19838210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of the MKL1/actin signaling pathway induces hormonal escape in estrogen-responsive breast cancer cell lines.
    Kerdivel G; Boudot A; Habauzit D; Percevault F; Demay F; Pakdel F; Flouriot G
    Mol Cell Endocrinol; 2014 Jun; 390(1-2):34-44. PubMed ID: 24721635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERα action and associates with the sensitivity of antiestrogen in breast cancer.
    Sun G; Wang C; Wang S; Sun H; Zeng K; Zou R; Lin L; Liu W; Sun N; Song H; Liu W; Zhou T; Jin F; Shan Z; Zhao Y
    Nucleic Acids Res; 2020 Nov; 48(19):10768-10784. PubMed ID: 32986841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
    Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer.
    Chen XS; Wang KS; Guo W; Li LY; Yu P; Sun XY; Wang HY; Guan YD; Tao YG; Ding BN; Yin MZ; Ren XC; Zhang Y; Chen CS; Ye YC; Yang JM; Cheng Y
    Theranostics; 2020; 10(4):1833-1848. PubMed ID: 32042339
    [No Abstract]   [Full Text] [Related]  

  • 32. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.
    Wright TM; Wardell SE; Jasper JS; Stice JP; Safi R; Nelson ER; McDonnell DP
    Mol Cancer Res; 2014 Dec; 12(12):1829-39. PubMed ID: 25100862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipocalin 2 promotes breast cancer progression.
    Yang J; Bielenberg DR; Rodig SJ; Doiron R; Clifton MC; Kung AL; Strong RK; Zurakowski D; Moses MA
    Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3913-8. PubMed ID: 19237579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
    Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S
    Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells.
    Kim MR; Choi HK; Cho KB; Kim HS; Kang KW
    Cancer Sci; 2009 Oct; 100(10):1834-41. PubMed ID: 19681904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SLUG is a direct transcriptional repressor of PTEN tumor suppressor.
    Uygur B; Abramo K; Leikina E; Vary C; Liaw L; Wu WS
    Prostate; 2015 Jun; 75(9):907-16. PubMed ID: 25728608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
    Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
    Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
    Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y
    Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells.
    Carpenter RL; Paw I; Dewhirst MW; Lo HW
    Oncogene; 2015 Jan; 34(5):546-57. PubMed ID: 24469056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.